Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus DARICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus DARICON.
ANTRENYL vs DARICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
5 mg orally three times daily. Maximum dose: 15 mg per day.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Category C
Category C
Anticholinergic
Anticholinergic